Organization · Venture Capital
Polaris Partners
Polaris Partners is a multistage venture capital firm based in Boston, New York, and San Francisco, focusing on healthcare and life sciences. Founded in 1996, it has invested in over 400 companies, achieving more than 100 exits.
Overview
What Polaris Partners does
What Polaris Partners is
Polaris Partners is a multistage venture capital firm based in Boston, New York, and San Francisco, focusing on healthcare and life sciences. Founded in 1996, it has invested in over 400 companies, achieving more than 100 exits.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 1996
- Approximate age
- About 30 years
- Structured capabilities
- Funder
- Last reviewed
- February 26, 2026
Official channels
Find Polaris Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
Polaris Partners as a funder
Investment thesis
Three specialized strategies: healthcare/life sciences venture, profitable B2B SaaS growth, and biomedical innovation. 30-year track record with 35 IPOs. 400+ healthcare companies backed, 50+ therapies to market.
Focus narrative
Polaris operates three specialized strategies: (1) core venture for healthcare/life sciences, (2) growth fund for profitable founder-owned B2B SaaS companies with $4-20M revenue, and (3) innovation fund turning academic biomedical research into companies. 400+ healthcare companies backed with 50+ therapies brought to market. 65LAB in Singapore for cross-border biotech.
Value beyond capital
Polaris brings nearly 30 years of deep healthcare and life sciences expertise with 400+ companies backed and 50+ therapies to market. The growth fund offers a unique proposition for profitable SaaS founders seeking capital while retaining significant ownership. 65LAB Singapore provides cross-Atlantic/Asia biotech formation bridge.
Terms and economics
- Typical check
- $10,000,000–$50,000,000
- Sweet spot
- $20,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
- Regions
- AsiaNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 412
- Investments in the last 12 months
- 5
- Last recorded investment
- December 1, 2025
- Recorded notable exits
- Datadog, Trulia, BarkBox, and NASDAQ
Portfolio context
412 companies invested with 6 unicorns, 35 IPOs, and 159 acquisitions. Notable: Datadog, Trulia, BarkBox, Neumora (NASDAQ, $2.58B), CAMP4 (NASDAQ). Recent: Leyden Labs ($70M Series B), Freenome (exit Dec 2025).
Common questions
What to know about Polaris Partners
Upseed classifies Polaris Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
February 26, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.